SURMOUNT-4 Trial: What Happens When You Stop Tirzepatide — The Weight Regain Data

SURMOUNT-4: The Weight Regain Question Answered

Perhaps no question in obesity medicine generates more anxiety than: "What happens when I stop the medication?" The SURMOUNT-4 trial, published in JAMA in January 2024 by Aronne et al., provided the definitive answer for tirzepatide using an elegant randomized withdrawal design that has become one of the most cited studies in the field [1].

The Critical Question

Weight regain after stopping anti-obesity medications has been documented with every drug class:

• Phentermine: Rapid regain within weeks of discontinuation
• Orlistat: Gradual regain over 6-12 months
• Semaglutide: Two-thirds of weight loss regained within one year (STEP 1 extension)

The question for tirzepatide was whether its dual GIP/GLP-1 mechanism might provide more durable effects, or whether the same pattern would emerge.

Study Design

SURMOUNT-4 used a novel randomized withdrawal design:

Phase 1 — Open-Label Lead-In (Weeks 0-36):

• 670 adults with obesity (BMI ≥30 or ≥27 with comorbidity) without diabetes
• All received tirzepatide, escalated to maximum tolerated dose (10 or 15 mg)
• 36 weeks of open-label treatment

Phase 2 — Randomized Withdrawal (Weeks 36-88):

• Participants who completed the lead-in and achieved ≥5% weight loss were randomized 1:1
• Continue group: Continued tirzepatide at their current dose for 52 more weeks
• Switch group: Switched to placebo for 52 weeks
• Double-blind from week 36 onward

This design allowed researchers to observe both the full trajectory of continued treatment AND the natural history of weight regain after stopping [1].

Results: The Diverging Curves

The results painted a stark picture of two very different trajectories:

Weight Change from Randomization (Week 36) to Week 88:

• Continue tirzepatide: -5.5% additional loss (total from baseline: -25.3%)
• Switch to placebo: +14.0% regain (total from baseline: -9.9%)
• Treatment difference: -19.4 percentage points (P<0.001)

At the Point of Randomization (Week 36):

• Both groups had lost approximately 20.9% of body weight
• Both groups had achieved similar cardiometabolic improvements

By Week 88:

• The continue group had lost a total of 25.3% — approaching bariatric surgery territory
• The switch group had regained more than half of their initial weight loss
• The curves diverged dramatically and continuously from week 36 onward [1].

Cardiometabolic Reversal

The weight regain was accompanied by reversal of metabolic improvements:

The metabolic reversal closely tracked the weight regain, demonstrating that the cardiometabolic benefits of tirzepatide are weight-dependent and require ongoing treatment to maintain [1].

The Chronic Disease Argument

SURMOUNT-4 has become the cornerstone evidence for treating obesity as a chronic disease:

The Analogy:

• Stopping tirzepatide and expecting weight to stay off is like stopping blood pressure medication and expecting blood pressure to remain normal
• Obesity is driven by biological mechanisms (hormonal, neurological, genetic) that persist regardless of prior weight loss
• The body actively defends its higher weight set point through compensatory mechanisms

Biological Mechanisms of Regain:

1. Metabolic adaptation: Reduced resting metabolic rate persists after weight loss
2. Hormonal rebound: Hunger hormones (ghrelin) increase; satiety hormones decrease
3. Neural adaptation: Brain appetite centers reset to pre-treatment levels
4. Adipose signaling: Fat cells release signals promoting weight restoration

Positive Findings: Continued Treatment Works

While the regain data is sobering, the continued treatment data is encouraging:

• 25.3% total weight loss at 88 weeks with continued tirzepatide
• No evidence of tolerance — weight loss continued beyond 36 weeks
• Sustained metabolic benefits throughout the treatment period
• Well-tolerated over the full 88-week treatment duration

This suggests that for patients who respond to tirzepatide, long-term continued treatment produces progressively better outcomes [1].

Implications for Patients and Providers

For Patients:

• Plan for long-term treatment if tirzepatide is effective
• Weight regain after stopping is not a personal failure — it's biology
• Some residual weight loss may persist even after stopping
• Discuss long-term treatment plans with your healthcare provider before starting

For Healthcare Providers:

• Counsel patients about the chronic nature of obesity before initiating treatment
• Develop long-term treatment plans, not just short-term weight loss goals
• Monitor patients who discontinue for early signs of regain
• Consider dose reduction rather than complete discontinuation if cost or side effects are concerns

For Payers and Policymakers:

• Long-term coverage of anti-obesity medications is medically necessary
• The cost of treating obesity-related complications exceeds the cost of ongoing pharmacotherapy
• Coverage restrictions that limit treatment duration are not evidence-based

References

1. Aronne LJ, Sattar N, Horn DB, et al. "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial." JAMA. 2024;331(1):38-48. PubMed: 38078870

2. Wilding JPH, Batterham RL, Davies M, et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide." Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564. PubMed: 35441470

3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022;387(3):205-216. PubMed: 35658024